Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor/Ivacaftor in young children with Cystic Fibrosis
NCT03601637Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2018
- Primary completion
- Oct 2021
- Countries
- 2
01
Overview
Phase 3, open-label trial in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Sep 2018; status: completed.
02
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03601637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601637.